Guidelines for clinical trials in melasma

British Journal of Dermatology

Volumn 156, Issue SUPPLE. 1, 2006, Pages 21-28

  Pandya, A ^a   Berneburg, M ^b   Ortonne, J P ^c   Picardo, M ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Clinical trials; Guidelines; Management; Melasma

Indexed keywords

DERMATOLOGICAL AGENT;

CHLOASMA; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRY SKIN; EROSION; ERYTHEMA; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PIGMENT DISORDER; POSTINFLAMMATORY HYPERPIGMENTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN BURNING SENSATION; SKIN DEFECT; SKIN INFLAMMATION; SKIN IRRITATION; SKIN REDNESS;

CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; HEALTH STATUS INDICATORS; HUMANS; MELANOSIS; SKIN;

EID: 33751349432     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07590.x     Document Type: Review

References (15)

1. Altman DG, Schulz KF, Moher D et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Int Med 2001; 134:663-94.
2. Moher D, Schultz KF, Altman DG, for the CONSORT Group.The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet 2001; 357:1191-4.
3. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol 1995; 131:1453-7.
4. Grimes PE, Kelly P, Totok H, Willis I. Community-based trial of a triple combination agent for the treatment of facial melasma. Cutis 2006; 77:177-84.
5. Im S, Kim J, On WY, Kang WH. Increased expression of a melanocytes-stimulating hormone in the lesional skin of melasma. Br J Dermatol 2002; 146:165-7.
6. Balkrishnan R, McMichael AJ, Camacho FT et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003; 149:572-7.
7. Fleischer AB Jr, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol 2000; 42:459-67.
8. Kimbrough-Green CK, Griffiths CEM, Finkel LJ et al. Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol 1994; 130:727-33.
9. Diffey BL, Oliver RJ, Farr PM. A portable instrument for quantifying erythema induced by ultraviolet radiation. Br J Dermatol 1984; 3:663-72.
10. Van den Kerckhove E, Staes F, Flour M et al. Reproducibility of repeated measurements on healthy skin with Minolta Chromameter CR-300. Skin Res Tech 2001; 7:56-9.
11. Anderson RR. Polarized light examination and photography of the skin. Arch Dermatol 1991; 127:1000-5.
12. Petit L, Piérard GE. Analytic quantification of solar lentigines lightening by a 2% hydroquinone-cyclodextrin formulation. Eur Acad Dermatol Venereol 2003; 17:546-9.
13. Kang WH, Yoon KH, Lee ES et al. Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol 2002; 146:228-37.
14. Dominguez AR, Balkrishnan R, Elizey AR, Pandya AG. Melasma in Latina patients: cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol 2006; 55:59-66.
15. Im S, Hann S-K, Kang W-H. (eds) New Concepts of Melasma and Postinflammatory Hyperpigmentation. Seoul, South Korea: Dongil Publishing Company, 2002.